What does this research mean for the field?

A nickel(II) complex containing diclofenac exhibits nanomolar potency against breast cancer stem cells by inducing necroptosis and promoting immunotherapeutic activation. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research examines the potential of a nickel(II) complex with diclofenac to induce necroptosis in breast cancer stem cells.

May 20, 2026Inorganic Chemistry Frontiers0 citationsOpen Access

A Necroptosis-Inducing Nickel(II) Complex for Immunotherapeutic Activation of Breast Cancer Stem Cells

ABAlexandra BrownUniversity of Leicester MCMinhui CuiChinese Academy of Sciences XFXiao FengUniversity of Leicester

Key Points

This research examines the potential of a nickel(II) complex with diclofenac to induce necroptosis in breast cancer stem cells.
The study utilized a nickel(II) complex containing diclofenac.
Potency was assessed against breast cancer stem cells, with performance measured in nanomolar concentrations.
The nickel(II) complex showed nanomolar potency towards breast cancer stem cells, with an effectiveness greater than 264-fold compared to standard measures.

Abstract

The immunotherapeutic anti-cancer stem cell (CSC) properties of a nickel(II) complex containing non-steroidal anti-inflammatory drug, diclofenac is reported. The nickel(II) complex 4 displays nanomolar potency towards breast CSCs, >264-fold greater...

问 AI

Bookmark

View Full Paper